Clinical data and samples from cancer patients with 10 different types of the disease were analyzed, and the researchers observed that individuals with liver, head and neck, and stomach cancers, who have lower levels of this protein in their tumors had higher chances of survival.
When the researchers suppressed those genes in mouse models of glaucoma they were able to regenerate the damaged axons. The findings could eventually lead to developing therapies for patients of stroke, spinal cord damage, or traumatic brain injuries—avenues that don't currently exists.
According to Myriad, it is the first and only genetic test approved by the FDA as a CDx designed to help identify patients with metastatic pancreatic cancer who have a germline BRCA mutation and are candidates for treatment with Lynparza.
Combining wearable devices, handheld devices and digital apps lets researchers tell the difference between people with early dementia and those without it.
Semen could be considered a liquid biopsy of the organs of male reproductive system—specifically, of the prostate gland. This is convenient. Semen is, potentially,...
Promega’s MSI testing is designed to functionally measure the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) that occurs in certain types of solid tumors.
The study's authors suggested their work could lead to a combination antiviral therapy for COVID-19, which could be especially helpful to unvaccinated people who become infected and to vaccinated people who experience waning immunity.
DNA methylation could improve outcomes via more accurate diagnoses of indolent or aggressive tumors requiring different treatment regimens
Later this year, combined company plans to launch QIAstat-Dx, designed for use in oncology and respiratory or gastrointestinal infections
A wider reach—in patients and data—promises better outcomes.
Broader, more diverse genomic data sets allow better training of polygenic risk score algorithms, moving them from research models into the clinic.
This year we highlight a range of leaders in precision medicine ranging from infectious disease experts to CRISPR researchers to company founders.